BBP - Virtus LifeSci Biotech Products ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
40.35
-0.56 (-1.37%)
As of 10:17AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close40.91
Open38.44
Bid39.30 x 800
Ask40.16 x 800
Day's Range36.20 - 40.65
52 Week Range34.56 - 46.39
Volume5,890
Avg. Volume2,457
Net Assets24.9M
NAV40.87
PE Ratio (TTM)N/A
Yield0.00%
YTD Daily Total Return-2.57%
Beta (5Y Monthly)1.51
Expense Ratio (net)0.79%
Inception Date2014-12-16
  • A Guide to Biotech ETF Investing
    Zacks

    A Guide to Biotech ETF Investing

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

  • Biotech Tops in November: Best ETFs & Stocks
    Zacks

    Biotech Tops in November: Best ETFs & Stocks

    The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

  • ETF Database

    Best & Worst Monthly Performers: November 21 Edition

    Here is a look at the 25 best and 25 worst ETFs from the past trading month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as potential starting points for those looking to take on either short or long positions. Likewise, traders can also use this list to spot potential trend reversal opportunities that may offer a generous risk/reward. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.

  • Investopedia

    The Medicines Company Soars Amid Acquisition Whispers

    The Medicines Company climbed to an all-time high Tuesday after takeover rumors surfaced. Play the momentum using these tactical ideas.

  • Biotech ETFs Surge on a Flurry of Positive News
    Zacks

    Biotech ETFs Surge on a Flurry of Positive News

    The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

  • Top and Flop ETFs So Far in Q2
    Zacks

    Top and Flop ETFs So Far in Q2

    The top ETF stories so far this second quarter linger around upbeat U.S. economic data points and the U.S.-China trade talks.

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zacks

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

  • A Spread of Top-Ranked ETFs That Crushed the Market in Q1
    Zacks

    A Spread of Top-Ranked ETFs That Crushed the Market in Q1

    We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank 1 or 2 which are expected to outperform in the quarter ahead.

  • 5 ETFs Shining With Green Returns & More Room to Run
    Zacks

    5 ETFs Shining With Green Returns & More Room to Run

    These ETFs are in the green this year and are up for more gains.

  • Top ETF Stories of February
    Zacks

    Top ETF Stories of February

    Inside the top ETF events of the month of February.